KATELYN WEATHERFORD: Open Payments
NPI 1376158279 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$884 in 20 payments from 11 companies in 2025. Trend: 2023 $280 · 2024 $242 · 2025 $884
Food & beverage: $884
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. | 2 | $233 |
| ABBVIE INC. | 7 | $172 |
| Xeris Pharmaceuticals, Inc. | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Pharmacosmos Therapeutics Inc. | 1 | $95 |
| Cranial Technologies, Inc | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $29 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $15 |
Products named: Arikayce, VRAYLAR, GVOKE HYPOPEN, MONOFERRIC, Doc Band, ZORYVE, Dexcom G6 Transmitter, QULIPTA.
Industry payments across TX — which companies pay providers there.
